Hematopoietic Cell Transplantation for Myelodysplastic Syndrome — CPB 0836 | AETNA Coverage Update

Aetna modified CPB 0836 for hematopoietic cell transplantation (HCT) in myelodysplastic syndrome, effective December 10, 2025. Here's what billing teams need to know.

Aetna, a CVS Health company, updated its HCT coverage policy under CPB 0836 Aetna system, tightening the criteria that determine when allogeneic transplantation clears medical necessity — and drawing a harder line on what stays experimental. The Aetna hematopoietic cell transplantation coverage policy directly affects claims billed under CPT codes 38205, 38230, 38240, and 38242, plus HCPCS S2150. If your facility handles bone marrow or stem cell transplant billing for Aetna-insured MDS patients, this update changes your authorization and documentation requirements now.

Quick-Reference Table

Aetna Hematopoietic Cell Transplantation Coverage Criteria and Medical Necessity Requirements 2025

The Aetna HCT coverage policy under CPB 0836 is specific about who qualifies. Aetna considers allogeneic HCT — both ablative and non-myeloablative — medically necessary for MDS patients who meet all three of these conditions: intermediate-risk or high-risk MDS classification, failure to respond to prior therapy, and an available HLA-compatible donor.

That's not a flexible list. All three criteria must be documented before Aetna will recognize medical necessity. If your team bills CPT 38240 (allogeneic HPC transplantation per donor) or CPT 38230 (bone marrow harvesting, allogeneic) without documentation of all three criteria, expect a claim denial.

HLA typing codes 86813 and 86817 are referenced in the policy as supporting codes. Make sure HLA compatibility is documented in the medical record — not just referenced in a transplant consult note. Aetna will look for specificity here.

Repeat allogeneic HCT also has a defined medical necessity path. Aetna covers it for primary graft failure, failure to engraft, or late relapse — defined as relapse occurring more than 18 months after the original HCT. This is salvage therapy, and the 18-month threshold is a hard line. Document the original transplant date and relapse date explicitly in every claim packet.

The policy does not specify a separate prior authorization requirement in its text, but CPB 0836 governs high-cost transplant services. You should assume prior authorization is required and confirm with Aetna's transplant pre-certification team before scheduling. Operating without prior auth on a transplant episode is a reimbursement risk your facility cannot afford.

The billing guidelines for this policy align with Aetna's broader pattern on complex HCT indications — they want risk stratification evidence, treatment history, and donor compatibility confirmed upfront. Build that documentation into your pre-transplant workflow now, before December 10, 2025.

Aetna HCT for MDS Exclusions and Non-Covered Indications

Two categories land firmly in experimental, investigational, or unproven territory under CPB 0836. Know these before you submit.

Early relapse after allogeneic HCT is not covered. If a patient relapses within 18 months of their original transplant, Aetna will not approve a repeat allogeneic HCT under this policy. The policy draws a clean line: less than 18 months is early relapse and experimental; more than 18 months is late relapse and covered as salvage. Your billing team and your transplant coordinators both need to know this threshold.

Autologous HCT for MDS is also experimental across the board. Aetna's position is that autologous transplantation for this indication lacks established effectiveness — so CPT 38241 (autologous HPC transplantation), CPT 38232 (autologous bone marrow harvesting), and CPT 38206 (autologous blood-derived HPC harvesting) are not covered for MDS under any circumstances in this policy.

This is not a gray area. If a physician orders autologous HCT for an MDS patient with Aetna coverage, bill it expecting denial. You'll need to either document a compelling exception argument or have an ABN in place before the procedure. Talk to your compliance officer before billing autologous codes for MDS under Aetna.

Coverage Indications at a Glance

Aetna HCT Billing Guidelines and Action Items 2025

The effective date of December 10, 2025 gives your team time to get this right. Use it.

CPT, HCPCS, and ICD-10 Codes for HCT Under CPB 0836

Covered CPT Codes (When Selection Criteria Are Met)

Covered HCPCS Codes (When Selection Criteria Are Met)

Not Covered / Experimental CPT Codes

Key ICD-10-CM Diagnosis Codes

All D46.x codes map to the MDS spectrum. Use the most specific subcategory your physician documents. Coding to D46.9 by default when a more specific subtype is documented is a payer audit risk — and it undermines your medical necessity argument for high-risk or intermediate-risk classifications.